India Globalization Capital/$IGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About India Globalization Capital
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Ticker
$IGC
Sector
Primary listing
AMEX
Industry
Pharmaceuticals
Headquarters
Employees
70
Website
IGC Metrics
BasicAdvanced
$30M
-
-$0.09
1.45
-
Price and volume
Market cap
$30M
Beta
1.45
52-week high
$0.46
52-week low
$0.25
Average daily volume
5M
Financial strength
Current ratio
1.283
Quick ratio
0.214
Long term debt to equity
2.275
Total debt to equity
3.76
Profitability
EBITDA (TTM)
-6.828
Gross margin (TTM)
48.70%
Net profit margin (TTM)
-560.27%
Operating margin (TTM)
-585.84%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-49.91%
Return on equity (TTM)
-104.33%
Valuation
Price to revenue (TTM)
21.674
Price to book
4.6
Price to tangible book (TTM)
6.5
Price to free cash flow (TTM)
-5.22
Free cash flow yield (TTM)
-19.16%
Free cash flow per share (TTM)
-0.069
Growth
Revenue change (TTM)
-5.50%
Earnings per share change (TTM)
-57.88%
3-year revenue growth (CAGR)
47.38%
10-year revenue growth (CAGR)
-16.46%
3-year earnings per share growth (CAGR)
-32.33%
10-year earnings per share growth (CAGR)
-11.41%
IGC News
AllArticlesVideos
IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025
Accesswire·1 week ago
IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
Accesswire·2 weeks ago
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for India Globalization Capital stock?
India Globalization Capital (IGC) has a market cap of $30M as of August 01, 2025.
What is the P/E ratio for India Globalization Capital stock?
The price to earnings (P/E) ratio for India Globalization Capital (IGC) stock is 0 as of August 01, 2025.
Does India Globalization Capital stock pay dividends?
No, India Globalization Capital (IGC) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next India Globalization Capital dividend payment date?
India Globalization Capital (IGC) stock does not pay dividends to its shareholders.
What is the beta indicator for India Globalization Capital?
India Globalization Capital (IGC) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.